SCYNEXIS, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company that develops innovative antifungal therapies to treat and prevent difficult-to-treat and drug-resistant fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections, vulvovaginal candidiasis (VVC), and recurrent VVC. The company offers BREXAFEMME (ibrexafungerp) tablets as an FDA-approved oral treatment for VVC and recurrent VVC in females; its lead product candidate ibrexafungerp, a novel triterpenoid antifungal available in oral and intravenous formulations, targets invasive candidiasis/candidemia, invasive aspergillosis, and other systemic fungal diseases; and SCY-247, an oral triterpenoid antifungal in development for invasive candidiasis with Phase 2 studies planned to yield proof-of-concept data in 2026. Founded in 1999 and headquartered in Jersey City, New Jersey, SCYNEXIS operates primarily in the United States with licensing and collaboration agreements including GlaxoSmithKline (GSK), Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., and others for the development, manufacture, and commercialization of ibrexafungerp across various regions. Recent developments include a October 2025 resolution of a dispute with GSK via a new license agreement that provides SCYNEXIS with $24.8 million in one-time payments received in Q4 2025, extending its cash runway beyond two years; GSK's 2023 exclusive global license (excluding greater China and select countries) for ibrexafemme commercialization with upfront and milestone payments; and November 2025 federal funding awarded to a Hackensack Meridian CDI-Johns Hopkins collaboration utilizing SCYNEXIS's triterpenoid platform for novel antifungal compounds.
SCYNEXIS Announces One-for-Eight Reverse Stock Split
SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update
SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
SCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD Therapeutics Transcript
Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million
SCYNEXIS Announces $40.0 Million Private Placement
SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update
SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247
CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors
Financial Survey: SCYNEXIS (NASDAQ:SCYX) and KalVista Pharmaceuticals (NASDAQ:KALV)
SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK
SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update
SCYNEXIS (SCYX) to Release Earnings on Wednesday
SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study
SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)
SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Squarepoint Ops LLC Takes Position in SCYNEXIS, Inc. (NASDAQ:SCYX)